Collaboration And Option Agreement Sample Contracts

Voyager Therapeutics, Inc. – Securities and Exchange Commission. Double Asterisks Denote Omissions. COLLABORATION AND OPTION AGREEMENT by and Between VOYAGER THERAPEUTICS, INC. AND ABBVIE BIOTECHNOLOGY LTD (March 14th, 2018)

This COLLABORATION AND OPTION AGREEMENT (this "Agreement") is entered into and made effective as of February 16, 2018 (the "Effective Date"), by and between Voyager Therapeutics, Inc., a Delaware corporation, having its principal place of business at 75 Sidney Street, Cambridge, MA 02139 ("Voyager"), and AbbVie Biotechnology Ltd, a corporation organized under the laws of Bermuda having its principal place of business at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda ("AbbVie"). Voyager and AbbVie shall be referred to herein individually as a "Party" and collectively as the "Parties".

Syros Pharmaceuticals, Inc. – Confidential Materials Omitted and Filed Separately With the Exhibit 10.22 Securities and Exchange Commission. Double Asterisks Denote Omissions. TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT Between SYROS PHARMACEUTICALS, INC. And INCYTE CORPORATION Dated as of January 8, 2018 (March 12th, 2018)

This Target Discovery, Research Collaboration and Option Agreement (this "Agreement") is made effective as of January 8, 2018 (the "Effective Date") by and between Syros Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 620 Memorial Drive, Suite 300, Cambridge, Massachusetts 02139 ("Syros") and Incyte Corporation, a Delaware corporation having its principal place of business at 1801 Augustine Cut-Off, Wilmington, Delaware 19803 ("Incyte"). Syros and Incyte are each referred to herein by name or as a "Party" or, collectively, as "Parties".

ImmunoGen, Inc. – COLLABORATION AND OPTION AGREEMENT Between IMMUNOGEN, INC. And JAZZ PHARMACEUTICALS IRELAND LIMITED Dated August 28, 2017 (November 9th, 2017)

This Collaboration and Option Agreement (this "Agreement") is made effective as of August 28, 2017 (the "Effective Date") by and between ImmunoGen, Inc., a Massachusetts corporation ("ImmunoGen"), with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, and Jazz Pharmaceuticals Ireland Limited, a corporation organized under the laws of Ireland ("Jazz"), with its principal place of business at Waterloo Exchange, Waterloo Road, Dublin 4, Ireland. ImmunoGen and Jazz are sometimes each hereinafter referred to individually as a "Party" and collectively as the "Parties."

ImmunoGen, Inc. – Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products Strengthens Jazz Hematology/Oncology Portfolio With Options for Innovative Development Candidates IMGN779 and IMGN632 ImmunoGen to Receive a $75 Million Upfront Payment, Up to $100 Million in Research Support, a Co-Commercialization Option, and Potential Future Opt-In Fees, Milestones and Royalties ImmunoGen Conference Call to Be Held Today at 8:00 AM EDT; Jazz Conference Call to Be Held Today at 4:30 PM EDT (August 29th, 2017)

DUBLIN and Waltham, Mass. August 29, 2017 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and ImmunoGen, Inc. (Nasdaq: IMGN) today announced that the companies have entered into a collaboration and option agreement granting Jazz Pharmaceuticals exclusive, worldwide rights to opt into development and commercialization of two early-stage, hematology-related antibody-drug conjugate (ADC) programs, as well as an additional program to be designated during the term of the agreement. The programs covered under the agreement include IMGN779, a CD33-targeted ADC for the treatment of acute myeloid leukemia (AML) in Phase 1 testing, and IMGN632, a CD123-targeted ADC for hematological malignancies expected to enter clinical testing before the end of the year.

Threshold Pharmaceuticals – CONFIDENTIAL TREATMENT REQUESTED Research Collaboration and Option Agreement (May 15th, 2017)

This Research Collaboration and Option Agreement (this Agreement) is made effective as of October 31, 2016 (Effective Date) by and between Millennium Pharmaceuticals, Inc., with a principal office at 40 Landsdowne Street, Cambridge, MA 02139 (Telephone: 617-679-7000, Facsimile: 617-374-0074), a wholly-owned subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), and Molecular Templates, Inc. with a principal office at 9301 Amberglen Boulevard, Suite 100, Austin, TX 78729 (MTI). MTI and Takeda each will be referred to herein as a Party and together as the Parties.

Amendment 5 to the Collaboration and Option Agreement (March 9th, 2017)

This Amendment 5 to the Collaboration and Option Agreement (the "Amendment") is made and entered into as of December 15, 2016 (the "Amendment Effective Date"), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America ("OncoMed"), and Bayer Pharma AG, a German corporation located at Mullerstrasse 178, 13353 Berlin, Germany which previously acted under the name Bayer Schering Pharma AG ("BSP"). OncoMed and BSP are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Amendment 4 to the Collaboration and Option Agreement (November 1st, 2016)

This Amendment 4 to the Collaboration and Option Agreement (the "Amendment") is made and entered into by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America ("OncoMed"), and Bayer Pharma AG, a German corporation located at Mullerstrasse 178, 13353 Berlin, Germany which previously acted under the name Bayer Schering Pharma AG ("BSP"). OncoMed and BSP are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Globeimmune Inc – Amendment #5 to the Collaboration and Option Agreement (November 13th, 2015)

THIS AMENDMENT #5 TO THE COLLABORATION AND OPTION AGREEMENT (together with any appendices attached hereto, this "Amendment #5") is made and entered into as of July 31, 2015 (the "Amendment #5 Effective Date"), by and between GlobeImmune, Inc., a Delaware corporation located at 1450 Infinite Drive, Louisville, Colorado 80027, United States of America ("GlobeImmune"), and Celgene Corporation, a Delaware corporation located at 86 Morris Avenue, Summit, New Jersey 07901, United States of America ("Celgene"). GlobeImmune and Celgene are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Amendment No. 7 to Collaboration and Option Agreement (May 4th, 2015)

This Amendment No. 7 to the Agreement (this Amendment No. 7) is entered into as of March 19, 2015 (the Amendment Effective Date) by and between Cytokinetics, Incorporated (Cytokinetics or CK), a Delaware corporation, having its principal place of business at 280 East Grand Ave., South San Francisco, California 94080 and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (Amgen).

Sevion Therapeutics, Inc. – Collaboration and Option Agreement (February 17th, 2015)

This Collaboration and Option Agreement (the "Agreement") is entered into as of December 18, 2014 (the "Effective Date") by and between Fabrus, Inc., a Delaware corporation ("Company"), having an address of 4045 Sorrento Valley Blvd, San Diego, California 92121, U.S.A., and CNA Development, LLC, a Delaware Limited Liability Company corporation with its office at Street C #475, Los Frailes Industrial Park, Guaynabo PR 00969 ("Janssen").

Globeimmune Inc – Contract (June 16th, 2014)

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Globeimmune Inc – Contract (June 4th, 2014)

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Globeimmune Inc – Contract (May 21st, 2014)

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Globeimmune Inc – Amendment #3 to the Collaboration and Option Agreement (May 21st, 2014)

THIS AMENDMENT #3 TO THE COLLABORATION AND OPTION AGREEMENT (together with any appendices attached hereto, this Amendment #3) is made and entered into as of June 16, 2011 (the Amendment #3 Effective Date), by and between GlobeImmune, Inc., a Delaware corporation located at 1450 Infinite Drive, Louisville, Colorado 80027, United States of America (GlobeImmune), and Celgene Corporation, a Delaware corporation located at 86 Morris Avenue, Summit, New Jersey 07901, United States of America (Celgene). GlobeImmune and Celgene are sometimes referred to herein individually as a Party and collectively as the Parties.

Globeimmune Inc – Amendment # 1 to the Collaboration and Option Agreement (March 17th, 2014)

This is an Amendment (Amendment) to the Collaboration and Option Agreement dated May 14th 2009 (the Agreement) by and between Celgene Corporation, a Delaware corporation having a place of business at 86 Morris Avenue, Summit, New Jersey 07901 (Celgene), and GlobeImmune, Inc., a Delaware corporation having a place of business at 1450 Infinite Drive, Louisville, Colorado 80027 (GlobeImmune).

Globeimmune Inc – Contract (March 17th, 2014)

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Globeimmune Inc – Amendment # 2 to the Collaboration and Option Agreement (March 17th, 2014)

This is a Second Amendment (Amendment #2) to the Collaboration and Option Agreement dated May 14th 2009 (the Agreement) by and between Celgene Corporation, a Delaware Corporation having a place of business at 86 Morris Avenue, Summit, New Jersey 07901 (Celgene), and GlobeImmune, Inc., a Delaware Corporation having a place of business at 1450 Infinite Drive, Louisville, Colorado 80027 (GlobeImmune).

Globeimmune Inc – Amendment #3 to the Collaboration and Option Agreement (March 17th, 2014)

THIS AMENDMENT #3 TO THE COLLABORATION AND OPTION AGREEMENT (together with any appendices attached hereto, this Amendment #3) is made and entered into as of June 16, 2011 (the Amendment #3 Effective Date), by and between GlobeImmune, Inc., a Delaware corporation located at 1450 Infinite Drive, Louisville, Colorado 80027, United States of America (GlobeImmune), and Celgene Corporation, a Delaware corporation located at 86 Morris Avenue, Summit, New Jersey 07901, United States of America (Celgene). GlobeImmune and Celgene are sometimes referred to herein individually as a Party and collectively as the Parties.

Amendment 2 to the Collaboration and Option Agreement (November 13th, 2013)

THIS AMENDMENT 2 TO THE COLLABORATION AND OPTION AGREEMENT (the Amendment) is made and entered into on August 27, 2013 (the Amendment Date), by and between OncoMed Pharmaceuticals, Inc. a Delaware corporation located at 800 Chesapeake Drive. Redwood City, California 94063. United States of America (OncoMed), and Bayer Pharma AG, a German corporation located at Mullerstrasse 178, 13353 Berlin, Germany which previously acted under the name Bayer Schering Pharma AG (BSP). OncoMed and BSP are sometimes referred to herein individually as a Party and collectively as the Parties.

Xencor – Collaboration and Option Agreement (October 25th, 2013)

THIS COLLABORATION AND OPTION AGREEMENT (Agreement) dated as of December 22, 2010 (Effective Date), is entered into between XENCOR, INC., a Delaware corporation having its principal place of business at 111 West Lemon Avenue, Monrovia, CA 91016 (Xencor) and AMGEN INC., a Delaware corporation, having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799 (Amgen). Amgen and Xencor are sometimes referred to herein individually as a Party and collectively as the Parties. Capitalized terms used herein shall have the definitions set forth in Article 1.

Xencor – Collaboration and Option Agreement (October 11th, 2013)

THIS COLLABORATION AND OPTION AGREEMENT (Agreement) dated as of December 22, 2010 (Effective Date), is entered into between XENCOR, INC., a Delaware corporation having its principal place of business at 111 West Lemon Avenue, Monrovia, CA 91016 (Xencor) and AMGEN INC., a Delaware corporation, having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799 (Amgen). Amgen and Xencor are sometimes referred to herein individually as a Party and collectively as the Parties. Capitalized terms used herein shall have the definitions set forth in Article 1.

Amendment No. 6 to Collaboration and Option Agreement (August 7th, 2013)

This Amendment No. 6 to the Agreement (this Amendment No. 6) is entered into as of June 11, 2013 (the Amendment Effective Date) by and between Cytokinetics, Incorporated (Cytokinetics), a Delaware corporation, having its principal place of business at 280 East Grand Ave., South San Francisco, California 94080 and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (Amgen).

Tengion – Collaboration and Option Agreement (July 5th, 2013)

This Collaboration and Option Agreement (this "Agreement") dated the 28th day of June, 2013 (the "Effective Date") is by and among Tengion, Inc., a Delaware corporation having its principal office at 3929 Westpoint Blvd., Suite G, Winston-Salem, NC 27103 ("Tengion"), Celgene Corporation, a Delaware corporation having its principal office at 86 Morris Avenue, Summit, NJ 07901 ("Celgene"), and Celgene European Investment Company LLC, a Delaware limited liability company and wholly-owned subsidiary of Celgene ("CEIC" and, together with Celgene, the "Celgene Companies"). Tengion, Celgene and CEIC may each be referred to herein individually as a "Party" and collectively as the "Parties."

Tengion – Collaboration and Option Agreement (July 5th, 2013)

This Collaboration and Option Agreement (this "Agreement") dated the 28th day of June, 2013 (the "Effective Date") is by and among Tengion, Inc., a Delaware corporation having its principal office at 3929 Westpoint Blvd., Suite G, Winston-Salem, NC 27103 ("Tengion"), Celgene Corporation, a Delaware corporation having its principal office at 86 Morris Avenue, Summit, NJ 07901 ("Celgene"), and Celgene European Investment Company LLC, a Delaware limited liability company and wholly-owned subsidiary of Celgene ("CEIC" and, together with Celgene, the "Celgene Companies"). Tengion, Celgene and CEIC may each be referred to herein individually as a "Party" and collectively as the "Parties."

Tengion – Collaboration and Option Agreement (July 5th, 2013)

This Collaboration and Option Agreement (this "Agreement") dated the 28th day of June, 2013 (the "Effective Date") is by and among Tengion, Inc., a Delaware corporation having its principal office at 3929 Westpoint Blvd., Suite G, Winston-Salem, NC 27103 ("Tengion"), Celgene Corporation, a Delaware corporation having its principal office at 86 Morris Avenue, Summit, NJ 07901 ("Celgene"), and Celgene European Investment Company LLC, a Delaware limited liability company and wholly-owned subsidiary of Celgene ("CEIC" and, together with Celgene, the "Celgene Companies"). Tengion, Celgene and CEIC may each be referred to herein individually as a "Party" and collectively as the "Parties."

Amendment 1 to the Collaboration and Option Agreement (October 25th, 2012)

THIS AMENDMENT 1 TO THE COLLABORATION AND OPTION AGREEMENT (the Amendment) is made and entered into on August 1st, 2012 (the Amendment Date), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (OncoMed), and Bayer Pharma AG, a German corporation located at Mullerstrasse 178, 13353 Berlin, Germany which previously acted under the name Bayer Schering Pharma AG (BSP). OncoMed and BSP are sometimes referred to herein individually as a Party and collectively as the Parties.

Globeimmune Inc – Amendment #3 to the Collaboration and Option Agreement (August 16th, 2012)

THIS AMENDMENT #3 TO THE COLLABORATION AND OPTION AGREEMENT (together with any appendices attached hereto, this Amendment #3) is made and entered into as of June 16, 2011 (the Amendment #3 Effective Date), by and between GlobeImmune, Inc., a Delaware corporation located at 1450 Infinite Drive, Louisville, Colorado 80027, United States of America (GlobeImmune), and Celgene Corporation, a Delaware corporation located at 86 Morris Avenue, Summit, New Jersey 07901, United States of America (Celgene). GlobeImmune and Celgene are sometimes referred to herein individually as a Party and collectively as the Parties.

Globeimmune Inc – Contract (August 16th, 2012)

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Collaboration and Option Agreement by and Between Oncomed Pharmaceuticals, Inc. And Bayer Schering Pharma Ag Dated June 15, 2010 (July 5th, 2012)

THIS COLLABORATION AND OPTION AGREEMENT (the Agreement) is made and entered into as of June 15, 2010 (the Effective Date), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (OncoMed), and Bayer Schering Pharma AG, a German corporation located at Mullerstrasse 178, 13353 Berlin, Germany (BSP). OncoMed and BSP are sometimes referred to herein individually as a Party and collectively as the Parties.

Globeimmune Inc – Contract (July 2nd, 2012)

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Globeimmune Inc – Amendment # 2 to the Collaboration and Option Agreement (July 2nd, 2012)

This is a Second Amendment (Amendment #2) to the Collaboration and Option Agreement dated May 14th 2009 (the Agreement) by and between Celgene Corporation, a Delaware Corporation having a place of business at 86 Morris Avenue, Summit, New Jersey 07901 (Celgene), and GlobeImmune, Inc., a Delaware Corporation having a place of business at 1450 Infinite Drive, Louisville, Colorado 80027 (GlobeImmune).

Globeimmune Inc – Amendment #3 to the Collaboration and Option Agreement (July 2nd, 2012)

THIS AMENDMENT #3 TO THE COLLABORATION AND OPTION AGREEMENT (together with any appendices attached hereto, this Amendment #3) is made and entered into as of June 16, 2011 (the Amendment #3 Effective Date), by and between GlobeImmune, Inc., a Delaware corporation located at 1450 Infinite Drive, Louisville, Colorado 80027, United States of America (GlobeImmune), and Celgene Corporation, a Delaware corporation located at 86 Morris Avenue, Summit, New Jersey 07901, United States of America (Celgene). GlobeImmune and Celgene are sometimes referred to herein individually as a Party and collectively as the Parties.

Globeimmune Inc – Amendment # 1 to the Collaboration and Option Agreement (July 2nd, 2012)

This is an Amendment (Amendment) to the Collaboration and Option Agreement dated May 14th 2009 (the Agreement) by and between Celgene Corporation, a Delaware corporation having a place of business at 86 Morris Avenue, Summit, New Jersey 07901 (Celgene), and GlobeImmune, Inc., a Delaware corporation having a place of business at 1450 Infinite Drive, Louisville, Colorado 80027 (GlobeImmune).

Collaboration and Option Agreement by and Between Oncomed Pharmaceuticals, Inc. And Bayer Schering Pharma Ag Dated June 15, 2010 (May 11th, 2012)

THIS COLLABORATION AND OPTION AGREEMENT (the Agreement) is made and entered into as of June 15, 2010 (the Effective Date), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (OncoMed), and Bayer Schering Pharma AG, a German corporation located at Mullerstrasse 178, 13353 Berlin, Germany (BSP). OncoMed and BSP are sometimes referred to herein individually as a Party and collectively as the Parties.

Fluidigm Corp. – CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION Amendment #1 to the Collaboration and Option Agreement Dated May 17, 2010 by and Between Fluidigm Corporation and Novartis Vaccines and Diagnostics, Inc. (April 4th, 2011)

Incorporating the terms and conditions of the Collaboration and Option Agreement made effective May 17, 2010 (hereinafter referred to as the Agreement), made by and between Novartis Vaccines and Diagnostics, Inc. (Novartis) and Fluidigm Corporation (Fluidigm), the Agreement is amended, effective as of March 15, 2011.